Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ondine BiomedicalFRA:VF5 -0.87%37 3-Year EBITDA Growth Rate is 16.80% as of Dec. 2025, which is 305% above its 10-year median of 4.15. GuruFocus rates FRA:VF5 with a GF Score™ of 37/100 and a GF Value™ of €0.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 1,127 Biotechnology companies, Ondine Biomedical ranks better than 52.26% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 13.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ondine Biomedical was 53.90% per year. The lowest was -128.40% per year. And the median was 4.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ondine Biomedical 3-Year EBITDA Growth Rate Related Terms
FRA:VF5 vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Ondine Biomedical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.80% mean?
Ondine Biomedical (FRA:VF5) has a 3-Year EBITDA Growth Rate of 16.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ondine Biomedical and its competitors. This is 305% above median its historical median of 4.15. According to the industry distribution chart, Ondine Biomedical ranks #538 out of 1127 companies in the Biotechnology industry, placing it in the top 47.7%.
Is Ondine Biomedical's 3-Year EBITDA Growth Rate too high?
Ondine Biomedical's current 3-Year EBITDA Growth Rate of 16.80% is 305% above median its 10-year median of 4.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Ondine Biomedical's value of 16.80% is 12.8% above this industry median. Based on the distribution chart, Ondine Biomedical ranks #538 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ondine Biomedical has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #538 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Ondine Biomedical in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Ondine Biomedical's value of 16.80% is 12.8% above this benchmark. While the company's 10-year median is 4.15 vs. the industry median of 14.90, Ondine Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ondine Biomedical's current 3-Year EBITDA Growth Rate of 16.80% is 12.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ondine Biomedical and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ondine Biomedical's current 3-Year EBITDA Growth Rate is 16.80%, which is 305% above median its own 10-year median of 4.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.11 — trading 26.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.80%, which is 305% above median its 10-year median of 4.15 and 12.8% above the Biotechnology industry median of 14.90. Ondine Biomedical's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current 3-Year EBITDA Growth Rate is 16.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.11 is trading 26.7% above its estimated GF Value™ of €0.09.
GuruFocus considers Ondine Biomedical to be Modestly Overvalued.
Key valuation signals for FRA:VF5:
3-Year EBITDA Growth Rate: 16.80% (305% above median its 10-year median of 4.15)
GF Value™: €0.09 vs. price of €0.11 (26.7% above fair value)
Industry Position: 12.8% above the Biotechnology median (#538 of 1127)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
37GF Score
Get the complete analysis for FRA:VF5
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
